KRAS and cancer: While some clinical trials attempted a drug repurposing idea, many clinical trials undertook the analysis of new strategies in PDAC – from immunotherapy agents that use TIGIT checkpoint inhibition and TKI/new targeted therapeutics, to the use of antibody-drug conjugates and newer PC methods such as T cell receptor T cell therapy or mDC3/8-KRAS cancer vaccines.